Friday, May 22, 2026 / Le vendredi 22 mai 2026

CONCURRENT SESSION – Part 1 (B): Bariatric Medicine Accepted Papers

SESSION CONCOMITANTE – Partie 1 (B) : Médecine bariatrique

4:05 – 4:12pm  / 16h05 – 16h12

Analysis of pharmacotherapy for weight loss in Ontario for 2022-2024-year period using IQVIA database

View Abstract Submission (PDF)

Learning objectives: 

• The aim of the study was to examine trends in the utilization of weight loss pharmacotherapy across Ontario.
• This retrospective study analysed data available through the IQVIA database from Dec 2022 to Oct 2024, focusing on six medications: semaglutide (Ozempic; Wegovy), tirzepatide (Mounjaro), liraglutide (Saxenda), naltrexone/bupropion (Contrave), and phentermine/topiramate (Qsymia).
• Prescription volumes for weight-loss medications increased substantially during the study period, particularly for semaglutide and tirzepatide. Northern Ontario exhibited the highest per-capita prescribing, while the Greater Toronto Area had the highest absolute numbers. 
• Private insurance and cash were the most common payment methods. 
• Disparities by age, sex, region, and payment method highlight gaps in equitable access to care. Monitoring these trends is essential for guiding policy, informing clinical practice, and ensuring all Ontarians can access effective obesity management. 

Presenter: 

Dr. Mirjana Jerkic, MD, PhD

Keenan Research Centre for Biomedical Science, Critical Care Research,
Unity Health Toronto St. Michael’s hospital, Toronto, Ontario, Canada


I am MD. PhD, working as Senior Research Associate in Dr Ori Rotstein Lab and the Biobank, at St. Michael’s Keenan Research Centre, Unity Health Toronto, affiliated to the University of Toronto. My main research interests include obesity, brain and lung injury, multiple sclerosis (MS), sepsis, stem cells, cellular pathways and mitochondria research. I’m involved in multiple clinical studies related to above mentioned topics.  
 

Analyse de la pharmacothérapie pour la perte de poids en Ontario pour la période de 2022 à 2024 à l'aide de la base de données IQVIA

Présentateur : 

Dr Mirjana Jerkic, MD, PhD

Keenan Research Centre for Biomedical Science, Critical Care Research,
Unity Health Toronto St. Michael’s hospital, Toronto, Ontario, Canada


I am MD. PhD, working as Senior Research Associate in Dr Ori Rotstein Lab and the Biobank, at St. Michael’s Keenan Research Centre, Unity Health Toronto, affiliated to the University of Toronto. My main research interests include obesity, brain and lung injury, multiple sclerosis (MS), sepsis, stem cells, cellular pathways and mitochondria research. I’m involved in multiple clinical studies related to above mentioned topics.